BioFortis Inc. has introduced its Next Generation Biobanking software platform for biomarker-based clinical research.
It will help pharmaceutical, government and academic research centers involved in biomarker-based clinical and translational studies to safely and effectively conduct externalized, science-driven collaborative studies.
As biomarker-based clinical research has become more commonplace, organizations have looked to biobanks to help drive these studies.
However, this approach poses significant challenges to conventional biobanks and their software.
The Next Generation Biobanking software platform is designed to overcome these challenges by harmonizing biospecimen data with clinical and molecular data in a collaborative environment that emphasizes scientific insights, while ensuring security and compliance.
At the core of the Next Generation Biobanking software solution is the Labmatrix® platform.
Labmatrix goes beyond the sample-centric workflows of conventional biobanking software by integrating patient, clinical, specimen, genetic and molecular assay data, to deliver holistic views of studies.
Multi-level user access control ensures that all collaborators can work effectively while maintaining relevant privacy and regulatory compliance objectives.
Driving scientific insights is one of the key benefits of Next Generation Biobanking software. Mining the wealth of data across studies, searching for the patterns within, and discovering knowledge requires tools that augment the user's own expertise.
To meet that need, the Next Generation Biobanking software platform provides Qiagram®, the award-winning visual ad hoc query tool.
Qiagram puts powerful query and knowledge discovery tools in the hands of the individual researcher.
Users "draw" their questions, interactively creating sophisticated queries, without the need to program or struggle with complicated query builders.
Answers are presented in configurable visualizations and dashboard widgets that can be shared to generate cross-study, cross-site and cross-group knowledge.
"Based on experiences with many pharmaceutical companies and academic centers, we believe that our Next Generation Biobanking software bridges the gap between conventional biobanking software and the needs of biomarker-based clinical research," commented BioFortis CEO, Jian Wang, PhD, "We consider it critical to empower researchers to perform these kinds of studies and deliver safer and effective clinical outcomes."
The BioFortis Next Generation Biobanking software platform will be demonstrated at Booth #226 at the 2012 Clinical Business Expo, September 19-20, Boston, MA.